As a leader in sleep medicine, Jazz’s nearly 20-year leadership has been built around tackling rare sleep conditions, all while centering on and giving a voice to the patient and caregiver experiences, such as those living with idiopathic hypersomnia. Read more about our plans to expand and spotlight the I Have IH awareness campaign at SLEEP 2023. 

For nearly 20 years, Jazz Pharmaceuticals has been a leader in sleep medicine. At SLEEP 2023, we reflect on our key learnings from the past two decades and reaffirm our longstanding commitment to the sleep community.

As both ASCO and SLEEP kick off this weekend, we are excited to meet with thought leaders and advocates across the oncology and sleep communities. By applying our pioneering approach and deep expertise in sleep disorders and oncology, we are working hard to advance industry-leading research and development so we can deliver new potential therapies to help even more patients.   

As we gear up for ASCO 2023, our team at Jazz is energized by the opportunity to share our research and learn about the latest advancements in cancer care, including difficult-to-treat cancers like small cell lung cancer (SCLC). It’s also an opportunity to highlight the importance of incorporating patients’ perspectives into our R&D process and supporting them and their families beyond treatment. 

March is an important month for us at Jazz. As a leader in sleep medicine, the month served as an awareness opportunity for those living with sleep disorders, as well as their caregivers, healthcare providers and our advocacy partners.

Jazz is committed to developing critical medicines for people living with serious neurological conditions including epilepsy. At this year’s 2022 American Epilepsy Society (AES) annual meeting, we will present data from six abstracts showcasing Jazz’s commitment to providing medicines for people living with rare forms of epilepsy with few treatment options.